PMID- 25360163
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220331
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 8
IP  - 6
DP  - 2014 Dec
TI  - mTOR pathway: A current, up-to-date mini-review (Review).
PG  - 2367-2370
AB  - Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that 
      was initially identified as the cellular target of rapamycin. This kinase 
      regulates cell growth, proliferation, motility and survival, as well as the gene 
      transcription and protein synthesis that are activated in response to hormones, 
      growth factors and nutrients. Results from preclinical studies have indicated 
      that factors antagonizing the mTOR pathway exert an antitumor effect on lung 
      cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated 
      that the inhibitors may be effective against lung carcinoma. The present study 
      explores the association between mTOR and lung carcinogenesis and describes the 
      clinical trials of mTOR inhibitors.
FAU - Zarogoulidis, Paul
AU  - Zarogoulidis P
AD  - Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle 
      University of Thessaloniki, Thessaloniki 57010, Greece.
FAU - Lampaki, Sofia
AU  - Lampaki S
AD  - Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle 
      University of Thessaloniki, Thessaloniki 57010, Greece.
FAU - Turner, J Francis
AU  - Turner JF
AD  - Interventional Pulmonary and Critical Care Medicine, Western Regional Medical 
      Center, Goodyear, Arizona 85338, USA.
FAU - Huang, Haidong
AU  - Huang H
AD  - Department of Respiratory Diseases Shanghai Hospital, Second Military University 
      Hospital, Shanghai 210000, P.R. China.
FAU - Kakolyris, Stylianos
AU  - Kakolyris S
AD  - Oncology Department, University General Hospital of Alexandroupolis, Democritus 
      University of Thrace, Alexandroupolis 68100, Greece.
FAU - Syrigos, Konstantinos
AU  - Syrigos K
AD  - Oncology Department, Sotiria General Hospital, University of Athens, Athens 
      11527, Greece.
FAU - Zarogoulidis, Konstantinos
AU  - Zarogoulidis K
AD  - Pulmonary Department-Oncology Unit, G. Papanikolaou General Hospital, Aristotle 
      University of Thessaloniki, Thessaloniki 57010, Greece.
LA  - eng
PT  - Journal Article
DEP - 20141010
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4214394
OTO - NOTNLM
OT  - lung cancer
OT  - mTOR
OT  - targeted therapy
EDAT- 2014/11/02 06:00
MHDA- 2014/11/02 06:01
PMCR- 2014/10/10
CRDT- 2014/11/01 06:00
PHST- 2014/06/02 00:00 [received]
PHST- 2014/09/26 00:00 [accepted]
PHST- 2014/11/01 06:00 [entrez]
PHST- 2014/11/02 06:00 [pubmed]
PHST- 2014/11/02 06:01 [medline]
PHST- 2014/10/10 00:00 [pmc-release]
AID - ol-08-06-2367 [pii]
AID - 10.3892/ol.2014.2608 [doi]
PST - ppublish
SO  - Oncol Lett. 2014 Dec;8(6):2367-2370. doi: 10.3892/ol.2014.2608. Epub 2014 Oct 10.